Stoked Bio is leveraging a biology-first approach in its AI-driven drug discovery platform to address the pressing challenges of antimicrobial resistance and glioblastoma. This innovative Mosaic platform integrates phenotypic screening with proprietary datasets and generative AI models, aiming to enhance the identification of therapeutics that effectively target both pathogens and cancer cells. The implications of this approach are substantial, as it not only accelerates drug discovery but also aims to reduce costs and attrition rates in early development.
In an upcoming GEN webinar, co-founder Jon Stokes, PhD, and CEO Jeff Skinner will elaborate on how their platform utilizes biological insights to advance the discovery of new antimicrobials and therapies for glioblastoma. Attendees can expect to gain insights into the operational mechanics of Stoked Bio’s Mosaic platform, including its integration of cutting-edge computational models with biological data. This discussion is particularly timely, given the urgent need for new treatment modalities in the face of evolving resistance mechanisms and tumor heterogeneity.
Use the database as your supply chain compass →
